Advanced Cell Technology Files Investigational New Animal Drug (INAD) Application With FDA to Treat 10 Different Disease Indications Using Pluripotent Stem Cells
Published: Sep 19, 2013
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it has filed an Investigational New Animal Drug (INAD) application with the Food and Drug Administration (FDA) to test its proprietary “off-the-shelf” mesenchymal stem cells (MSC) in a range of different disease indications.
Help employers find you! Check out all the jobs and post your resume.